Opportunity ID: 324918
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | W81XWH-20-ARP-CTA |
| Funding Opportunity Title: | DoD Autism, Clinical Trial Award |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement Grant |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | 2 |
| Assistance Listings: | 12.420 — Military Medical Research and Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 3 |
| Posted Date: | Feb 27, 2020 |
| Last Updated Date: | Mar 19, 2020 |
| Original Closing Date for Applications: | Jul 16, 2020 |
| Current Closing Date for Applications: | Jul 28, 2020 |
| Archive Date: | Aug 15, 2020 |
| Estimated Total Program Funding: | $6,880,000 |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
| Additional Information on Eligibility: | – |
Additional Information
| Agency Name: | Dept. of the Army — USAMRAA |
| Description: |
The ARP Clinical Trial Award supports research with the potential to have a major impact on the treatment or management of ASD. Funding from this award mechanism must support a clinical trial and may not be used for preclinical research studies. The FY20 ARP Clinical Trial Award seeks applications from all areas of clinical research. The ARP encourages applications that address critical needs of the ASD community in one or more of the following areas: • Dissemination/implementation of clinically validated interventions • Behavioral, cognitive, and other non-pharmacological therapies for ASD core symptoms or to alleviate co-occurring conditions • Pharmacological, genetic, and other biological treatments for ASD core symptoms or to alleviate co-occurring conditions • Improve diagnosis and access to services across the life span • Interventions promoting success in key transitions to adulthood for individuals living with ASD • Healthcare provider-focused training or tools to improve healthcare delivery for individuals with ASD across the life span and the continuum of care (i.e., primary care, urgent/emergent care, and disaster relief) • Cultural, socioeconomic, and gender factors in diagnosis, treatment efficacy, delivery, and access to services • Understanding heterogeneity in treatment response |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
CDMRP Help Desk
Phone: 301-682-5507 Email: help@eBRAP.org Email:help@eBRAP.org |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
| This modification is to make changes to the Submission Dates and Times on Page 1 of the Program Announcement. | Mar 19, 2020 | |
| The Program Announcement has been revised to address an inconsistency in the page limit for the SOW. | Feb 27, 2020 | |
| Feb 27, 2020 |
DISPLAYING: Synopsis 3
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | W81XWH-20-ARP-CTA |
| Funding Opportunity Title: | DoD Autism, Clinical Trial Award |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement Grant |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | 2 |
| Assistance Listings: | 12.420 — Military Medical Research and Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 3 |
| Posted Date: | Feb 27, 2020 |
| Last Updated Date: | Mar 19, 2020 |
| Original Closing Date for Applications: | Jul 16, 2020 |
| Current Closing Date for Applications: | Jul 28, 2020 |
| Archive Date: | Aug 15, 2020 |
| Estimated Total Program Funding: | $6,880,000 |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
| Additional Information on Eligibility: | – |
Additional Information
| Agency Name: | Dept. of the Army — USAMRAA |
| Description: |
The ARP Clinical Trial Award supports research with the potential to have a major impact on the treatment or management of ASD. Funding from this award mechanism must support a clinical trial and may not be used for preclinical research studies. The FY20 ARP Clinical Trial Award seeks applications from all areas of clinical research. The ARP encourages applications that address critical needs of the ASD community in one or more of the following areas: • Dissemination/implementation of clinically validated interventions • Behavioral, cognitive, and other non-pharmacological therapies for ASD core symptoms or to alleviate co-occurring conditions • Pharmacological, genetic, and other biological treatments for ASD core symptoms or to alleviate co-occurring conditions • Improve diagnosis and access to services across the life span • Interventions promoting success in key transitions to adulthood for individuals living with ASD • Healthcare provider-focused training or tools to improve healthcare delivery for individuals with ASD across the life span and the continuum of care (i.e., primary care, urgent/emergent care, and disaster relief) • Cultural, socioeconomic, and gender factors in diagnosis, treatment efficacy, delivery, and access to services • Understanding heterogeneity in treatment response |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
CDMRP Help Desk
Phone: 301-682-5507 Email: help@eBRAP.org Email:help@eBRAP.org |
DISPLAYING: Synopsis 2
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | W81XWH-20-ARP-CTA |
| Funding Opportunity Title: | DoD Autism, Clinical Trial Award |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement Grant |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | 2 |
| Assistance Listings: | 12.420 — Military Medical Research and Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 2 |
| Posted Date: | Feb 27, 2020 |
| Last Updated Date: | Mar 03, 2020 |
| Original Closing Date for Applications: | – |
| Current Closing Date for Applications: | Jul 16, 2020 |
| Archive Date: | Aug 15, 2020 |
| Estimated Total Program Funding: | $6,880,000 |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
| Additional Information on Eligibility: | – |
Additional Information
| Agency Name: | Dept. of the Army — USAMRAA |
| Description: |
The ARP Clinical Trial Award supports research with the potential to have a major impact on the treatment or management of ASD. Funding from this award mechanism must support a clinical trial and may not be used for preclinical research studies. The FY20 ARP Clinical Trial Award seeks applications from all areas of clinical research. The ARP encourages applications that address critical needs of the ASD community in one or more of the following areas: • Dissemination/implementation of clinically validated interventions • Behavioral, cognitive, and other non-pharmacological therapies for ASD core symptoms or to alleviate co-occurring conditions • Pharmacological, genetic, and other biological treatments for ASD core symptoms or to alleviate co-occurring conditions • Improve diagnosis and access to services across the life span • Interventions promoting success in key transitions to adulthood for individuals living with ASD • Healthcare provider-focused training or tools to improve healthcare delivery for individuals with ASD across the life span and the continuum of care (i.e., primary care, urgent/emergent care, and disaster relief) • Cultural, socioeconomic, and gender factors in diagnosis, treatment efficacy, delivery, and access to services • Understanding heterogeneity in treatment response |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
CDMRP Help Desk
Phone: 301-682-5507 Email: help@eBRAP.org Email:help@eBRAP.org |
DISPLAYING: Synopsis 1
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | W81XWH-20-ARP-CTA |
| Funding Opportunity Title: | DoD Autism, Clinical Trial Award |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement Grant |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | 2 |
| Assistance Listings: | 12.420 — Military Medical Research and Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Feb 27, 2020 |
| Last Updated Date: | Feb 27, 2020 |
| Original Closing Date for Applications: | – |
| Current Closing Date for Applications: | Jul 16, 2020 |
| Archive Date: | Aug 15, 2020 |
| Estimated Total Program Funding: | $6,880,000 |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
| Additional Information on Eligibility: | – |
Additional Information
| Agency Name: | Dept. of the Army — USAMRAA |
| Description: |
The ARP Clinical Trial Award supports research with the potential to have a major impact on the treatment or management of ASD. Funding from this award mechanism must support a clinical trial and may not be used for preclinical research studies. The FY20 ARP Clinical Trial Award seeks applications from all areas of clinical research. The ARP encourages applications that address critical needs of the ASD community in one or more of the following areas: • Dissemination/implementation of clinically validated interventions • Behavioral, cognitive, and other non-pharmacological therapies for ASD core symptoms or to alleviate co-occurring conditions • Pharmacological, genetic, and other biological treatments for ASD core symptoms or to alleviate co-occurring conditions • Improve diagnosis and access to services across the life span • Interventions promoting success in key transitions to adulthood for individuals living with ASD • Healthcare provider-focused training or tools to improve healthcare delivery for individuals with ASD across the life span and the continuum of care (i.e., primary care, urgent/emergent care, and disaster relief) • Cultural, socioeconomic, and gender factors in diagnosis, treatment efficacy, delivery, and access to services • Understanding heterogeneity in treatment response |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
CDMRP Help Desk
Phone: 301-682-5507 Email: help@eBRAP.org Email:help@eBRAP.org |
Related Documents
Packages
| Agency Contact Information: | CDMRP Help Desk Phone: 301-682-5507 Email: help@eBRAP.org Email: help@eBRAP.org |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| 12.420 | PKG00258609 | Feb 27, 2020 | Jul 28, 2020 | View |
Package 1
Mandatory forms
Optional forms
Share This Post, Choose Your Platform!
About the Author: osnqt
